Displaying 1 - 2 of 2
Much of the ongoing morbidity in patients suffering majordepressive disorders is related to current treatments failing to produce complete remission. Many patients can be considered to
have treatment-resistant depression (TRD), with failure to fully
remit with adequate doses and durations of 2 or more antidepressant trials [1, 2] . TRD is associated with greater disability, mortality, morbidity, somatic symptoms, risk of relapse and societal cost
[3, 4] . We report on a pilot study of mindfulness-based cognitive
therapy (MBCT) for TRD.
Much of the ongoing morbidity in patients suffering majordepressive disorders is related to current treatments failing to produce complete remission. Many patients can be considered to
have treatment-resistant depression (TRD), with failure to fully
remit with adequate doses and durations of 2 or more antidepressant trials [1, 2] . TRD is associated with greater disability, mortality, morbidity, somatic symptoms, risk of relapse and societal cost
[3, 4] . We report on a pilot study of mindfulness-based cognitive
therapy (MBCT) for TRD.